Alert Fellows Symposium — Registration Now Open
Skip to main

Clinical Trials

Share

The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. 

Clinical Trials - Recruiting

TitleSponsorOrgan TypeAges AcceptedExpected 
Completion 
Date
A Phase 2, randomized, partially blinded, controlled, dose-ranging study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VEL-101 in kidney transplant recipients. (RENGEVITY-201)Veloxis PharmaceuticalsKidney October 31, 2028
Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)Atara BiotherapeuticsAll organsAll agesJune 30, 2027
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)Atara BiotherapeuticsAll organsAll agesJune 30, 2027

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

BiogenKidney18-75
Tuesday, June 1, 2027
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver TransplantJohns Hopkins School of Medicine
 		Kidney, Liver13-25September 30, 2026
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation (CONCORD)Alexion Pharmaceuticals, Inc.Kidney18-75 
Monday, October 11, 2027
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (FREXERA)SanofiKidney18-70 
Monday, August 15, 2033

Clinical Trials - Active, Not Recruiting

TitleSponsorOrgan TypeAges AcceptedExpected 
Completion 
Date
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)                                                                                                                          AstraZenecaAll organs January 21, 2025
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)Hansa BiopharmaKidney18-70June 30, 2025
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationEledon PharmaceuticalsKidney18+March 31, 2025

Give Back

Make a difference in the field of transplantation by donating to support our cause.

Give

Sign up for AST eNews

This resource for transplant professionals shares AST news events and top articles in transplantation.

View Current Issue

Advertisements

This content was developed independently by AST and supported by a financial contribution from Sanofi